Currently the following drugs and substances are being formulated or under consideration as Novochizol aerosol formulations:
- Valsatran. Unlike Losatran, which is converted in the liver, to yield more potent metabolites, Valsatran exerts its effects directly and may prove more potent when delivered directly into the lungs. Valsatran-N has been formulated.
- Telmisartan. Telmisartan has demonstrated greater anti-inflammatory activity than valsartan in animal models of lung inflammation. Telmisartan-N is under development.
- Recombinant ACE2. The rationale of delivering recombinant ACE2 into the lungs of infected patients is tgo capture SARS-COV-2 viral particles with a decoy receptor and prevent further infection and endogenous ACE2 degradation. rACE2-N development is under consideration.
- Fluorescein. Fluorescein-N has been formulated for the purpose of demonstarting Novochizol Aerosol targeting inside the lungs and airways of experimental animals.